Clinical trials
Phase 1 Crohn Disease trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
12 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2013 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2020 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 7 |
| Completed | 3 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Second Affiliated Hospital of Wenzhou Medical University | 2 |
| Beijing Friendship Hospital | 1 |
| Benethera (Shaoxing) Biotechnology Co., Ltd. | 1 |
| Chengdu Zenitar Biomedical Technology Co., Ltd | 1 |
| GlaxoSmithKline | 1 |
| Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | 1 |
| Jinling Hospital, China | 1 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 1 |
| Takeda | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Crohn Disease | 12 |
| Colitis, Ulcerative | 3 |
| Vitamin D Deficiency | 2 |
| Arthritis, Juvenile | 1 |
| Arthritis, Rheumatoid | 1 |
| Autoimmune Diseases | 1 |
| Colonic Neoplasms | 1 |
| Dermatomyositis | 1 |
| Diverticulosis, Colonic | 1 |
| Inflammatory Bowel Diseases | 1 |
Trials
Showing 1 to 12 of 12. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.